X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 77.25 CNY -4.46% Market Closed
Market Cap: 31.4B CNY

EV/EBITDA
Enterprise Value to EBITDA

30.4
Current
33.5
Median
4.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
30.4
=
Enterprise Value
30.8B CNY
/
EBITDA
1B CNY
EBITDA Growth EV/EBITDA to Growth
CN
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Average EV/EBITDA: 17.4
30.4
32%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 430.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -657 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
20.2
2-Years Forward
EV/EBITDA
13.8
3-Years Forward
EV/EBITDA
14